Natural killer cells (NK cells) are lymphoid cells that play an important role in the immune system and are effective in killing infected or cancer cells.
NAM-NK has shown in pre-clinical studies to improve the killing efficacy and to overcome some of the limitations of culture expanded NK cells. The NK cells cultured with NAM display superior in-vivo homing, retention and proliferation.
NAM-NK potentiates direct killing mechanisms and secretion of inflammatory cytokines needed for the activation of additional lymphoid.
Gamida Cell is developing donor derived expanded NK cells with enhanced functionality as a treatment for cancer. The NAM-NK product is comprised of highly functional, robust cells that can be manufactured cost effectively and potentially as an off-the-shelf product.
A Phase 1 study will begin in H1/2017 for patients with refractory B-cell lymphoma and multiple myeloma in combination with specific antibodies.